International Journal of Hematology

, Volume 108, Issue 6, pp 607–614 | Cite as

KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell line

  • Hiroyuki Morita
  • Akihito Matsuoka
  • Jun-ichiro Kida
  • Hiroyuki Tabata
  • Kaoru Tohyama
  • Yumi Tohyama
Original Article


A microtubule-associated motor protein, kinesin-like family member 20A (KIF20A; also called MKlp2) is required for cytokinesis and contributes to intracellular vesicular trafficking. KIF20A plays a critical role in the development of several cancers, but its role in blood cells and hematological malignancies have not been studied. In the present study, we focused on the role of KIF20A in hematopoietic cells and possible involvement in myeloid neoplasms. We found that human leukemia cell lines and normal bone marrow CD34-positive cells stimulated by growth factors, but not mature peripheral blood cells, exhibit high KIF20A expression. We further found that HL60 cells, which originally express a large amount of KIF20A, showed decreased KIF20A expression in parallel with both neutrophil-like and macrophage-like differentiation-induction. KIF20A-knockdown using a lentivirus shRNA transfection system led to partial cell cycle arrest at the G2/M phase and frequent appearance of multinucleated cells. Treatment with a KIF20A-selective inhibitor, paprotrain enhanced the multinuclearity of KIF20A-knockdown cell clones and suppressed growth. The present study contributes to our understanding of the role of KIF20A in blood cells and leukemia cells in particular.


Kinesin-like family member Hematopoietic organ Cell cycle arrest Multinuclearity Cell differentiation 



This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and in part by a Kawasaki Medical School project grant.

Compliance with ethical standards

Conflict of interest

All authors have no conflict of interest to declare.


  1. 1.
    Lai F, Fernald AA, Zhao N, Le Beau MM. cDNA cloning, expression pattern, genomic structure and chromosomal location of RAB6KIFL, a human kinesin-like gene. Gene. 2000;248:117–25.CrossRefGoogle Scholar
  2. 2.
    Fontijn RD, Goud B, Echard A, Jollivet F, van Marle J, Pannekoek H, et al. The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis. Mol Cell Biol. 2001;21:2944–55.CrossRefGoogle Scholar
  3. 3.
    Gruneberg U, Neef R, Honda R, Nigg EA, Barr FA. Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2. J Cell Biol. 2004;166:167–72.CrossRefGoogle Scholar
  4. 4.
    Neef R, Klein UR, Kopajtich R, Barr FA. Cooperation between mitotic kinesins controls the late stages of cytokinesis. Curr Biol. 2006;16:301–7.CrossRefGoogle Scholar
  5. 5.
    Lee SH, McCormick F, Saya H. Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol. 2010;191:1069–77.CrossRefGoogle Scholar
  6. 6.
    Gasnereau I, Boissan M, Margall-Ducos G, Couchy G, Wendum D, Bourgain-Guglielmetti F, et al. KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis. Am J Pathol. 2012;180:131–40.CrossRefGoogle Scholar
  7. 7.
    Kitagawa M, Fung SY, Hameed UF, Goto H, Inagaki M, Lee SH. Cdk1 coordinates timely activation of MKlp2 kinesin with relocation of the chromosome passenger complex for cytokinesis. Cell Rep. 2014;7:166–79.CrossRefGoogle Scholar
  8. 8.
    Zhang Y, Liu J, Peng X, Zhu CC, Han J, Luo J, et al. KIF20A regulates porcine oocyte maturation and early embryo development. PLoS One. 2014;9:e102898.CrossRefGoogle Scholar
  9. 9.
    Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005;65:105–12.CrossRefGoogle Scholar
  10. 10.
    Taniuchi K, Furihata M, Saibara T. KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells. Neoplasia. 2014;16:1082–93.CrossRefGoogle Scholar
  11. 11.
    Duan J, Huang W, Shi H. Positive expression of KIF20A indicates poor prognosis of glioma patients. Onco Targets Ther. 2016;9:6741–9.CrossRefGoogle Scholar
  12. 12.
    Zhang W, He W, Shi Y, Gu H, Li M, Liu Z, et al. High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS One. 2016;11:e0167449.CrossRefGoogle Scholar
  13. 13.
    Liu SL, Lin HX, Qiu F, Zhang WJ, Niu CH, Wen W, et al. Overexpression of kinesin family member 20A correlates with disease progression and poor prognosis in human nasopharyngeal cancer: a retrospective analysis of 105 patients. PLoS One. 2017;12:e0169280.CrossRefGoogle Scholar
  14. 14.
    Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, et al. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37:36–42.CrossRefGoogle Scholar
  15. 15.
    Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016;27:62–8.CrossRefGoogle Scholar
  16. 16.
    Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24:748–55.CrossRefGoogle Scholar
  17. 17.
    Okamoto S, Tsujioka T, Suemori S, Kida J, Kondo T, Tohyama Y, et al. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci. 2016;107:1302–14.CrossRefGoogle Scholar
  18. 18.
    Tsujioka T, Yokoi A, Itano Y, Takahashi K, Ouchida M, Okamoto S, et al. Five-aza-20-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. Sci Rep. 2015;5:e16709.CrossRefGoogle Scholar
  19. 19.
    Yokoyama K, Kaji H, He J, Tanaka C, Hazama R, Kamigaki T, et al. Rab27a negatively regulates phagocytosis by prolongation of the actin-coating stage around phagosomes. J Biol Chem. 2011;286:5375–82.CrossRefGoogle Scholar
  20. 20.
    Liu J, Wang QC, Cui XS, Wang ZB, Kim NH, Sun SC. MKlp2 inhibitor paprotrain affects polar body extrusion during mouse oocyte maturation. Reprod Biol Endocrinol. 2013;11:117.CrossRefGoogle Scholar
  21. 21.
    Labrière C, Talapatra SK, Thoret S, Bougeret C, Kozielski F, Guillou C. New MKLP-2 inhibitors in the paprotrain series: design, synthesis and biological evaluations. Bioorg Med Chem. 2016;24:721–34.CrossRefGoogle Scholar
  22. 22.
  23. 23.
    Hao S, Chen C, Cheng T. Cell cycle regulation of hematopoietic stem or progenitor cells. Int J Hematol. 2016;103:487–97.CrossRefGoogle Scholar
  24. 24.
    BloodSpot. a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis Accessed 1 Aug 2018.
  25. 25.
    Esendagli G, Canpinar H, Yilmaz G, Kaymaz FF, Kansu E, Guc D. Fibronectin promotes the phorbol 12-myristate 13-acetate-induced macrophage differentiation in myeloid leukemia cells. Int J Hematol. 2009;89:167–72.CrossRefGoogle Scholar
  26. 26.
    Hagiwara Y, Kasukabe T, Kaneko Y, Niitsu N, Okabe-Kado J. Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells. Int J Hematol. 2010;92:136–43.CrossRefGoogle Scholar
  27. 27.
    Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 2016;35:990–1002.CrossRefGoogle Scholar
  28. 28.
    Stangel D, Erkan M, Buchholz M, Gress T, Michalski C, Raulefs S, et al. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. J Surg Res. 2015;197:91–100.CrossRefGoogle Scholar
  29. 29.
    Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013;11:291.CrossRefGoogle Scholar
  30. 30.
    Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017;108:73–80.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.Division of Biochemistry, Faculty of Pharmaceutical SciencesHimeji Dokkyo UniversityHyogoJapan
  2. 2.Department of Laboratory MedicineKawasaki Medical SchoolKurashikiJapan

Personalised recommendations